Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story 2 Healthcare Names That Could Get a Big Boost From EarningsSubmitted by Nathan Reiff. Posted: 1/20/2026. 
What You Need to Know - An acceleration from last quarter's 4% year-over-year growth in nutrition segment sales could help boost Abbott Laboratories' revenue performance.
- Intuitive Surgical's preliminary fourth-quarter earnings results led to a modest dip in share price, perhaps due to middling forecasted da Vinci procedure growth for 2026.
- Still, overall adoption and revenue growth rates remain high, and the temporary decline may be an opportunity for long-term investors.
Active traders expect companies in the healthcare sector to see significant share-price moves tied to milestones in the development of new therapies and medical products. Volatility in parts of the sector makes it high-risk but potentially high-reward. Another major catalyst for large share movements is healthcare earnings reports. The two companies below may be poised for immediate or longer-term growth depending on the signals their earnings releases send in late January. Analysts Expect Abbott to Overcome Nutrition Sluggishness Abbott Laboratories (NYSE: ABT) is a $211 billion healthcare giant that provides diagnostic tools, medical devices, pharmaceuticals and more, and is well known for its continuous glucose monitoring (CGM), cardiac and vascular products. The former CEO of Google calls it the most important thing to happen in 500, maybe 1,000 years of human society. A former U.S. Treasury Secretary says when your great-grandchildren write the history of this period, the political headlines will be the second or third story. The first story is something none of us have seen before. The dot-com collapse, global financial crisis, and COVID-19 pandemic don't compare to what's coming next. We may be entering a period of dramatic, almost unimaginable change. See the full warning and how to prepare now. Abbott's stock has produced a modest 4.3% gain over the past 12 months, underperforming the S&P 500. For the third quarter of 2025, Abbott met analyst expectations with earnings per share (EPS) of $1.30, but revenue missed by more than $31 million even though sales rose about 7% year-over-year (YOY). The main drag on revenue was the nutrition segment, which delivered only 4% YOY sales growth. Diagnostics sales in China also proved to be a headwind, pressured by tariffs and other trade issues. Still, the somewhat lackluster top- and bottom-line results may obscure bright spots heading into year-end, including a 17% YOY increase in CGM product sales to $2 billion. Investors will watch whether new high-protein, low-sugar launches for Ensure and Glucerna can reignite category growth; those products could boost the nutrition segment and help accelerate overall sales. Given earlier issues with volume-based procurement programs that weakened diagnostics sales in China, it may be unlikely Abbott fully resolved those concerns in the prior quarter. However, that may matter less if the company continues to perform well in medical devices and pharmaceuticals and if diagnostics sales in its core lab business (excluding China) remain strong. Wall Street appears confident going into Abbott's end-of-year earnings. Analysts at Barclays, Evercore ISI and others have reiterated Buy ratings or raised price targets in recent weeks. The consensus implies roughly 21% upside; 19 analysts rate ABT a Buy, while four rate it a Hold. Intuitive's Preliminary Earnings Dip Could Be a Hidden Opportunity Intuitive Surgical (NASDAQ: ISRG) is a large medical-device company whose product lineup is focused on robot-assisted surgical systems. Investors already have a preview of the company's fourth-quarter results thanks to preliminary results issued on Jan. 14, 2026: total quarterly worldwide procedures rose 18% YOY, supported by an aging population and growing demand for minimally invasive surgery. Intuitive's da Vinci system continues to see strong adoption, helping drive fourth-quarter revenue up 19% YOY to $2.87 billion. Despite those solid metrics, the market reacted to the preliminary release with a modest sell-off in ISRG shares. That dip likely reflected somewhat cautious 2026 guidance: Intuitive expects da Vinci procedures to rise 13%–15% in 2026, a slower pace than the 18% YOY growth seen in 2025. Still, Intuitive's long-term prospects remain robust, not only because of sustained demand for its systems but also due to its often-overlooked pipeline of imaging agents and other therapeutics. If the official fourth-quarter report provides a fuller picture of the company's strengths heading into the new year, shares could rebound from the earlier pullback. Analysts remain largely bullish: 18 rate ISRG a Buy, while nine rate it either a Hold or a Sell, and the consensus implies more than 16% upside.
| 
